A Comparison of Dexmedetomidine and Midazolam for ICU Sedation Guided by the Sedation-Agitation Scale (SAS)

• Shivangi Sharma

  Junior Resident

  Author

• Shrey Gupta

  Author

• Amit Kumar Jangid

  Author

Background:
Sedation is a cornerstone of critical care for mechanically ventilated patients in the Intensive Care Unit (ICU), balancing comfort with the need for early liberation from ventilation. Dexmedetomidine, a selective α₂-adrenoceptor agonist, offers a unique pharmacological profile compared to traditional agents like midazolam, with potential advantages in reducing ventilation duration and improving outcomes.

Objective:
This prospective, randomized, comparative study aimed to evaluate the efficacy and safety of dexmedetomidine versus midazolam for sedation in adult ICU patients requiring mechanical ventilation, guided by the Sedation-Agitation Scale (SAS).

Methods:
Sixty patients (18–65 years) were randomized into two groups (n=30 each): Group A (Dexmedetomidine) received a loading dose of 1 µg/kg over 10 minutes, followed by a maintenance infusion (0.2–1.0 µg/kg/h), while Group B (Midazolam) received a bolus of 0.03–0.1 mg/kg, followed by a maintenance infusion (0.02–0.2 mg/kg/h). Sedation was titrated to achieve an SAS score of 3–4. Primary outcomes included duration of mechanical ventilation and time to extubation after sedation cessation. Secondary outcomes included hemodynamic stability, adverse events, ICU length of stay, and 28-day mortality.

Results:
Dexmedetomidine significantly reduced the mean duration of mechanical ventilation (82.5 ± 18.2 vs. 105.8 ± 25.5 hours; p = 0.002) and time to extubation (19.8 ± 7.5 vs. 32.1 ± 11.8 hours; p < 0.001) compared to midazolam. While dexmedetomidine was associated with higher incidences of bradycardia (16.7% vs. 3.3%) and hypotension (23.3% vs. 13.3%), these were manageable. Midazolam showed higher rates of delayed awakening (26.7% vs. 6.7%) and agitation (23.3% vs. 10.0%). ICU length of stay was shorter in the dexmedetomidine group (7.8 ± 2.1 vs. 9.5 ± 3.0 days; p = 0.02), with a non-significant trend toward lower 28-day mortality (13.3% vs. 23.3%; p = 0.30).

Conclusion:
Dexmedetomidine provides superior sedation for mechanically ventilated ICU patients, enabling faster weaning from ventilation and shorter ICU stays compared to midazolam, despite a higher but manageable risk of hemodynamic adverse events. These findings support its use as a primary sedative agent in critical care, particularly when early extubation is a priority.

Copyright (c) 2026 Shivangi Sharma, Shrey Sharma, Amit Kumar Jangid (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.